Recombinant human endostatin

Phase 2Small molecule

PPeking University Third Hospital

Recombinant human endostatin is one of 116 small molecule programs targeting Breast Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

115

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerActive, not recruiting

Cervical CancerActive, not recruiting

GliomaRecruiting

Systemic TherapyNot yet recruiting

Breast CancerPreclinical

Active, not recruiting

Cervical CancerPreclinical

Active, not recruiting

GliomaPhase 2

Recruiting

Systemic TherapyPhase 2

Not yet recruiting

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Recombinant human endostatin

PPeking University Third Hospital

Phase 2

1 2

Blenoxane

Bristol-Myers Squibb

Preclinical

1 3

Neoadjuvant Treatment

SShanghai Zhongshan Hospital

Preclinical

1 4

Tianeptine

Pfizer

Preclinical

1 5

Diuretic

RReprieve Cardiovascular, Inc

Preclinical

1 6

Metfomin

UUniversity of Texas Southwestern Medical Center

Preclinical

1 7

Bisphosphonate

Amgen

Preclinical

2 8

Perflutren Lipid Microsphere

IImaRx Therapeutics

Preclinical

1 9

Silvadene

RRosalind Franklin University of Medicine and Science

Preclinical

1 10

QBX258

Novartis

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Not yet recruiting

Systemic Therapy

NCT06618391

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer3 trials

Adjuvant Vinorelbine Plus Cisplatin(NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer(NSCLC)

Completed·SShanghai Jiao Tong University School of Medicine·Phase 3·NCT01124253·250 enrolled

Efficacy and Safety of Recombinant Human Endostatin in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis

Unknown status·HHui Bu·Phase 4·NCT04356118·30 enrolled

Adjuvant Vinorelbine Plus Cisplatin (NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer

Unknown status·CChinese Academy of Sciences·Phase 3·NCT00576914·1,108 enrolled

Lung Cancer2 trials

Endostar Combination With Chemotherapy and EGFR-TKI in Lung Cancer Rechallenging Treatment After Acquired Resistance.

Unknown status·PPeking University Third Hospital·Phase 2/3·NCT02350361·60 enrolled

First-Line Treatment of Advanced Non-Small-Cell Lung Cancer With Negative Driver Gene: a Multicenter, Single-Arm Trial

Unknown status·QQianfoshan Hospital·Phase 2·NCT05574998·100 enrolled

Glioma2 trials

Modified CV Regimen in Optic Pathway Glioma

Recruiting·—·Phase 2·NCT05278715·75 enrolled

Study of Recombinant Human Endostatin Combined with Temozolomide and Irinotecan in Recurrent Gliomas

Recruiting·—·Phase 2·NCT04267978·109 enrolled

Epithelial Tumor1 trial

Second-Line Chemotherapy Combined With Endostatin for Recurrent/Metastatic HN Epithelial Tumors

Unknown status·SSun Yan·Phase 2·NCT03989830·53 enrolled

Unresectable1 trial

Recombinant Human Endostatin Continued Pumping Into Vein Combining With CCRT in Unresectable Stage III NSCLC

Completed·ZZhejiang Cancer Hospital·Phase 1/2·NCT01733589·73 enrolled

14 more indications

Hepatocellular Carcinoma1 trial

Recombinant Human Endostatin(Rh-endostatin) Combine With Radiotherapy in the Treatment of Hepatocellular Carcinoma(HCC)

Unknown status·—·Phase 2·NCT03208335·61 enrolled

Cervical Cancer1 trial

Envafolimab Combined With Endostar and Concurrent Chemoradiotherapy for Locally Advanced Primary Cervical Cancer

Not yet recruiting·PPeking University Third Hospital··NCT05879796·30 enrolled

Phase II Clinical Trial1 trial

A Phase II Clinical Trial of Chemotherapy With or Without Endostar® Continuous Intravenous Infusion in Refractory NPC

Unknown status·YYun-fei Xia·Phase 2·NCT02590133·328 enrolled

Durvalumab1 trial

Rh-Endostatin Combined With CCRT(50 Gy) Followed by Durvalumab Maintenance for the Treatment of Specific Phase III NSCLC

Unknown status·SShanghai Chest Hospital·Phase 4·NCT04613284·97 enrolled

Chemotherapy1 trial

Recombinant Human Endostatin Combined With Envafolimab and Synchronal Radiochemotherapy

Unknown status·TThe First Affiliated Hospital of Xinxiang Medical College·Phase 2·NCT06279754·30 enrolled

Colorectal Cancer1 trial

Envafolimab Combined With Endostatin in Recurrent or Metastatic MSS-type Colorectal Cancer

Unknown status·FFirst Affiliated Hospital Xi'an Jiaotong University·Phase 2·NCT05551247·30 enrolled

Metastatic Colorectal Cancer1 trial

Recombinant Human Endostatin in Combination With mFOLFOX6 in Patients With Metastatic Colorectal Cancer

Unknown status·FFudan University·Phase 1·NCT01310478·15 enrolled

Advanced Refractory Solid Tumors1 trial

Endostatin in Treating Patients With Advanced Refractory Solid Tumors

Completed·UUniversity of Wisconsin, Madison·Phase 1·NCT00004872

Systemic Therapy1 trial

Local Injection and Systemic Therapy in the Treatment of NSCLC.

Not yet recruiting·HHenan Cancer Hospital·Phase 2·NCT06618391·84 enrolled

Lung Adenocarcinoma1 trial

Endostar Durative Transfusion Combined With Chemotherapy in the Treatment of Advanced Lung Adenocarcinoma

Unknown status·—·Phase 4·NCT02804646·100 enrolled

Patients With Advanced Solid Tumors1 trial

Endostatin in Treating Patients With Advanced Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00004229·30 enrolled

Metastatic Melanoma1 trial

Rh-endostatin in Combination With Dacarbazine and Cisplatin as the First Line Therapy for Metastatic Melanoma

Unknown status·PPeking University Cancer Hospital & Institute·Phase 2·NCT03095079·70 enrolled

Breast Cancer1 trial

Breast Cancer Treatment Based on Organ-like Culture

Unknown status·XXijing Hospital··NCT03925233·300 enrolled

Pleural effusion1 trial

Intrapleural Administration of Bevacizumab Versus Endostar for Pleural Effusions in NSCLC

Unknown status·ZZhejiang University·Phase 2·NCT02005120·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 23 trial records for Recombinant human endostatin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Recombinant human endostatin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Recombinant human endostatin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Peking University Third Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: PPeking University Third Hospital

Recombinant human endostatin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Non-Small Cell Lung Cancer3 trials

Lung Cancer2 trials

Glioma2 trials

Epithelial Tumor1 trial

Unresectable1 trial

Hepatocellular Carcinoma1 trial

Cervical Cancer1 trial

Phase II Clinical Trial1 trial

Durvalumab1 trial

Chemotherapy1 trial

Colorectal Cancer1 trial

Metastatic Colorectal Cancer1 trial

Advanced Refractory Solid Tumors1 trial

Systemic Therapy1 trial

Lung Adenocarcinoma1 trial

Patients With Advanced Solid Tumors1 trial

Metastatic Melanoma1 trial

Breast Cancer1 trial

Pleural effusion1 trial

References

Drug Info

Quick Facts

Related News